OBSOLETE: Hyperlipoproteinemia type 5

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:70470
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Hyperlipoproteinemia type 5 (also called Type V hyperlipoproteinemia, or familial mixed hypertriglyceridemia) is a condition where the blood contains very high levels of certain fats, specifically triglycerides and particles called chylomicrons and VLDL (very low-density lipoprotein). This buildup of fats in the blood is sometimes called hypertriglyceridemia. The condition is marked as 'obsolete' in some medical databases because it is now better understood as part of a broader group of fat metabolism disorders rather than a single distinct disease. When fat levels in the blood become extremely high, the body struggles to clear them properly. This can lead to serious problems including inflammation of the pancreas (pancreatitis), which causes severe abdominal pain. People may also develop yellowish fatty deposits under the skin called xanthomas, and may experience abdominal discomfort, nausea, and an enlarged liver or spleen. Treatment focuses on lowering triglyceride levels through a combination of a very low-fat diet, avoiding alcohol, and medications such as fibrates (like fenofibrate) or omega-3 fatty acids. Managing underlying conditions like diabetes or obesity is also a key part of care. With proper management, many people can reduce their risk of serious complications like pancreatitis.

Also known as:

Key symptoms:

Very high triglyceride (fat) levels in the bloodSevere abdominal pain due to pancreatitis (inflamed pancreas)Yellowish fatty bumps on the skin (eruptive xanthomas)Enlarged liver or spleenNausea and vomitingCreamy or milky appearance of blood when drawnFatigue and general feeling of being unwellAbdominal bloating or discomfortMemory or thinking problems in severe cases

Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for OBSOLETE: Hyperlipoproteinemia type 5.

View clinical trials →

No actively recruiting trials found for OBSOLETE: Hyperlipoproteinemia type 5 at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: Hyperlipoproteinemia type 5 community →

No specialists are currently listed for OBSOLETE: Hyperlipoproteinemia type 5.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to OBSOLETE: Hyperlipoproteinemia type 5.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: Hyperlipoproteinemia type 5Forum →

No community posts yet. Be the first to share your experience with OBSOLETE: Hyperlipoproteinemia type 5.

Start the conversation →

Latest news about OBSOLETE: Hyperlipoproteinemia type 5

No recent news articles for OBSOLETE: Hyperlipoproteinemia type 5.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What triglyceride level is my target, and how will we know if treatment is working?,Should I have genetic testing to understand if this runs in my family?,What specific foods and drinks should I completely avoid?,Which medication is best for me, and what are the side effects I should watch for?,What are the warning signs of pancreatitis, and when should I go to the emergency room?,How often do I need blood tests to monitor my fat levels?,Are there any clinical trials or newer treatments I should know about?

Common questions about OBSOLETE: Hyperlipoproteinemia type 5

What is OBSOLETE: Hyperlipoproteinemia type 5?

Hyperlipoproteinemia type 5 (also called Type V hyperlipoproteinemia, or familial mixed hypertriglyceridemia) is a condition where the blood contains very high levels of certain fats, specifically triglycerides and particles called chylomicrons and VLDL (very low-density lipoprotein). This buildup of fats in the blood is sometimes called hypertriglyceridemia. The condition is marked as 'obsolete' in some medical databases because it is now better understood as part of a broader group of fat metabolism disorders rather than a single distinct disease. When fat levels in the blood become extreme

How is OBSOLETE: Hyperlipoproteinemia type 5 inherited?

OBSOLETE: Hyperlipoproteinemia type 5 follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does OBSOLETE: Hyperlipoproteinemia type 5 typically begin?

Typical onset of OBSOLETE: Hyperlipoproteinemia type 5 is adult. Age of onset can vary across affected individuals.